Targeting the NLRP3 inflammasome in inflammatory diseases

By M. Mangan, E. Olhava, W. Roush, H. Seidel, G. Glick, E. Latz. Nature reviews. Drug discovery, 2018

1,586 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/de05e86c448777c68935dd359a11f7e0c945bb46

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. G. van Loo
2. M. Lamkanfi
3. Hongbo Hu
4. Zhiqiang Zhang
5. Hui Yu
6. Huiyuan Zhang
7. Liangbin Lin

In Molecular Biology

1. G. van Loo
2. M. Lamkanfi

Citations in the corpus

• Pyroptosis in inflammatory diseases and cancer (2022, background): “P2X7 inhibitor Liver disease Prevents ATP-mediated activation of NLRP3 [83]”
• Inflammasomes in neuroinflammatory and neurodegenerative diseases (2019, background): “However, for most agents it is not known whether they directly target NLRP3 or indirectly act on the pathway via other mechanisms, hampering clinical development of these molecules (Mangan et al, 2018).”
• Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study (2020, background): “The NLRP3 inflammasome is currently the most characterized inflammasome.(81) The basal expression of NLRP3 is not sufficient to activate inflammasome, so under most conditions, before exposure to activation signals, NLRP3 requires priming signals, which involve a post-translational regulatory mechan”